Materials and methods
The effect of SYK inhibitor MRK-A on allergic airway responses was evaluated in IgE-mediated tracheal extravasation in rat, Brown Norway Ova rat models of allergic inflammation and the sheep inhaled ascaris allergen challenge model.
Results
MRK-A dose-dependently blocked IgE-mediated tracheal extravasation in rat. In a Brown Norway rat ovalbuminsensitized airway challenge model oral dosing of MRK-A led to a dose-dependent inhibition of airway inflammation. Intravenous dosing of MRK-A was able to significantly inhibit both early and late allergen-induced changes in airway resistance in an ascaris-sensitive sheep allergen challenge model as well as airway hyper responsiveness.
Conclusions
Here we demonstrated that SYK mechanism plays a significant role in several in vivo allergen challenge models. This ranges from simple PK/PD mast cells driven models such as the IgE-mediated tracheal extravasation to the more complex and clinically relevant sheep inhaled allergen challenge model.
